Clinical forecasting is now leveraging innovative informatics capabilities for more precise recruitment and endpoint projections during a study’s crucial…


Shire targets Allergan's dry-eye market share by pricing Xiidra at $5K per year--right on par with Restasis

Teva looks for $20B-plus from bond sale to finance Allergan deal

Teva expects Allergan deal close any day, it says while lifting guidance

Shire's new dry-eye approval means it's time for an Allergan showdown

Rebates, bundling to keep Allergan's Botox growing in face of competition, specialists say

Allergan's brand recognition, rebates keep aesthetics unit primed for growth: Specialists

Mayne vaults ahead in U.S. with $652M deal for Teva/Allergan meds

Big Pharma harvests far more from transplants than homegrown meds

Allergan's stellar Viberzi coverage bodes well for future launches: Analyst

Analyst cuts Allergan generics sales estimates as Teva deal close nears